Literature DB >> 24348124

Perampanel: a selective AMPA antagonist for treating seizures.

Gregory L Krauss1.   

Abstract

Perampanel is a selective, noncompetitive AMPA receptor antagonist that has recently been approved for treating localization-related epilepsy. This article reviews the pharmacology, clinical development, efficacy, and safety/tolerability of perampanel.

Entities:  

Year:  2013        PMID： 24348124      PMCID： PMC3854741          DOI： 10.5698/1535-7597-13.6.269

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


  12 in total

1.  Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.

Authors:  Takahisa Hanada; Yutaka Hashizume; Naoki Tokuhara; Osamu Takenaka; Naohiro Kohmura; Aichi Ogasawara; Shinji Hatakeyama; Makoto Ohgoh; Masataka Ueno; Yukio Nishizawa
Journal:  Epilepsia       Date:  2011-06-02       Impact factor: 5.864

2.  Tolerability and safety of perampanel: two randomized dose-escalation studies.

Authors:  G L Krauss; M Bar; V Biton; J A Klapper; I Rektor; N Vaiciene-Magistris; D Squillacote; D Kumar
Journal:  Acta Neurol Scand       Date:  2011-08-29       Impact factor: 3.209

3.  Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Authors:  G L Krauss; J M Serratosa; V Villanueva; M Endziniene; Z Hong; J French; H Yang; D Squillacote; H B Edwards; J Zhu; A Laurenza
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

4.  Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Authors:  Gregory L Krauss; Emilio Perucca; Elinor Ben-Menachem; Patrick Kwan; Jerry J Shih; David Squillacote; Haichen Yang; Michelle Gee; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

5.  Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

Authors:  Jacqueline A French; Gregory L Krauss; Bernhard J Steinhoff; David Squillacote; Haichen Yang; Dinesh Kumar; Antonio Laurenza
Journal:  Epilepsia       Date:  2012-08-20       Impact factor: 5.864

Review 6.  Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist.

Authors:  M A Rogawski; T Hanada
Journal:  Acta Neurol Scand Suppl       Date:  2013

7.  Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.

Authors:  Barry E Gidal; Jim Ferry; Oneeb Majid; Ziad Hussein
Journal:  Epilepsia       Date:  2013-06-17       Impact factor: 5.864

8.  Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Authors:  I Rektor; G L Krauss; M Bar; V Biton; J A Klapper; N Vaiciene-Magistris; R Kuba; D Squillacote; M Gee; D Kumar
Journal:  Acta Neurol Scand       Date:  2012-08-23       Impact factor: 3.209

9.  Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Authors:  Bernhard J Steinhoff; Elinor Ben-Menachem; Philippe Ryvlin; Simon Shorvon; Lynn Kramer; Andrew Satlin; David Squillacote; Haichen Yang; Jin Zhu; Antonio Laurenza
Journal:  Epilepsia       Date:  2013-05-10       Impact factor: 5.864

10.  Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): a novel, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) receptor antagonist.

Authors:  Shigeki Hibi; Koshi Ueno; Satoshi Nagato; Koki Kawano; Koichi Ito; Yoshihiko Norimine; Osamu Takenaka; Takahisa Hanada; Masahiro Yonaga
Journal:  J Med Chem       Date:  2012-12-04       Impact factor: 7.446
View more
  5 in total

1.  DRESS associated with perampanel administration in a child with drug-resistant epilepsy.

Authors:  Kozue Shimabukuro; Frances Gibbon; Justin Kerstetter; Cynthia Tinsley; Stephen Ashwal
Journal:  Neurology       Date:  2014-10-31       Impact factor: 9.910

Review 2.  Dendritic structural plasticity and neuropsychiatric disease.

Authors:  Marc P Forrest; Euan Parnell; Peter Penzes
Journal:  Nat Rev Neurosci       Date:  2018-03-16       Impact factor: 34.870

3.  Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.

Authors:  Alexandra Rohracher; Gudrun Kalss; Markus Leitinger; Claudia Granbichler; Ildiko Deak; Judith Dobesberger; Giorgi Kuchukhidze; Aljoscha Thomschewski; Julia Höfler; Eugen Trinka
Journal:  Ther Adv Neurol Disord       Date:  2016-09-01       Impact factor: 6.570

4.  Effect of adjunctive perampanel on the quality of sleep and daytime somnolence in patients with epilepsy.

Authors:  Montserrat González-Cuevas; Odile Romero; Manuel Toledo; Manuel Quintana; Roser Cambrodí; Estevo Santamarina; Maria José Jurado; Alex Ferrer; Xavier Salas-Puig
Journal:  Epilepsy Behav Case Rep       Date:  2016-10-21

5.  Perampanel inhibition of AMPA receptor currents in cultured hippocampal neurons.

Authors:  Chao-Yin Chen; Lucas Matt; Johannes Wilhelm Hell; Michael A Rogawski
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.